A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION

drug protocol number
MO43156
drug sponsor
Roche
drug study
ATEZOLIZUMAB (TECENTRIQ)
drug trial site
King Fahad Specialist Hospital (Dammam)
drug status
Ongoing
drug phase